Background: The mechanism of action of safinamide, a new chemical entity, combines both dopaminergic and non-dopaminergic activity in producing benefit in patients with Parkinson's disease (PD).
Drug platforms Pilus-based vaccine for Group B StreptococcusA vaccine based on a chimeric protein could provide protection against Group B Streptococcus infection.The vaccine's chimeric protein, BP-2a, contained a domain of each one of the six type 2a pilus proteins.In mice, immunization with BP-2a protected against various type 2a pilus-carrying Group B Streptococcus strains compared with control saline immunization.Next steps include preclinical testing of BP-2a as a stand-alone vaccine and also as a carrier for a Group B Streptococcus conjugate vaccine, followed by Phase I studies.
Androulla Efstratiou3, Markus Hufnagel2, Mogens Kilian7, Mirjam Kunze2, Paula Kriz8, Graziella Orefici4, Laurence Seidel1, John Telford9 on behalf of the DEVANI Consortium Team 1.University Hospital of Liege, Belgium; 2.University of Freiburg, Germany 3.Health Protection Agency, London, United Kingdom; 4.Istituto Superiore di Sanita, Rome, Italy; 5.National Centre for Infectious Diseases, Sofia, Bulgaria; 6.University Hospital of Granada, Spain; 7.Aarhus University, Denmark; 8.National Public Health Institute, Prague, Czech Republic; 9.Novartis Vaccines and Diagnostics, Siena, Italy NEONATAL INVASIVE GROUP B STREPTOCOCCAL INFECTIONS IN EUROPE
The Global HIV Vaccine Enterprise convened a two-day workshop on August 10-11 2009, at the Fred Hutchison Cancer Research Center offices in Seattle, WA, to discuss the application of novel approaches,including systems biology, to HIV vaccine research and development. The goals of this Working Group were to identify key scientific issues and opportunities that have emerged since the Enterprise Scientific Strategic Plan1 was published in 2005, and to make recommendations to Enterprise stakeholders.
